Palouse Capital Management, Inc. Vertex Pharmaceuticals Inc Transaction History

Palouse Capital Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$343.0 - $410.68 $4,116 - $4,928	12 Added 0.4%	3,049 $1.24 Million
Q3 2023 Oct 23, 2023	BUY	$338.18 - $362.46 $338 - $362	1 Added 0.03%	3,037 $1.06 Million
Q2 2023 Aug 08, 2023	SELL	$314.42 - $351.91 $68,543 - $76,716	-218 Reduced 6.7%	3,036 $1.07 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $263,687 - $300,806	-931 Reduced 22.25%	3,254 $1.03 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $80,298 - $90,335	-281 Reduced 6.29%	4,185 $1.21 Million
Q3 2022 Oct 21, 2022	SELL	$273.83 - $305.53 $34,776 - $38,802	-127 Reduced 2.77%	4,466 $1.29 Million
Q2 2022 Jul 28, 2022	SELL	$234.96 - $292.55 $423,632 - $527,467	-1,803 Reduced 28.19%	4,593 $1.29 Million
Q1 2022 Apr 21, 2022	SELL	$221.42 - $260.97 $49,155 - $57,935	-222 Reduced 3.35%	6,396 $1.67 Million
Q4 2021 Jan 25, 2022	SELL	$177.01 - $223.45 $192,940 - $243,560	-1,090 Reduced 14.14%	6,618 $1.45 Million
Q3 2021 Oct 21, 2021	SELL	$181.39 - $202.99 $1.44 Million - $1.61 Million	-7,935 Closed	0 $0
Q2 2021 Jul 28, 2021	BUY	$187.49 - $221.1 $26,248 - $30,954	140 Added 1.8%	7,935 $1.6 Million
Q1 2021 May 11, 2021	BUY	$207.02 - $241.31 $503,886 - $587,348	2,434 Added 45.4%	7,795 $1.68 Million
Q4 2020 Feb 03, 2021	BUY	$207.01 - $276.09 $1.11 Million - $1.48 Million	5,361 New	5,361 $1.27 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Palouse Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Palouse Capital Management, Inc. with notifications on news.